[
  {
    "ts": null,
    "headline": "Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance",
    "summary": "On Wednesday, Charles River Laboratories International Inc (NYSE:CRL) reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million. In the fourth quarter of 2024, the operating margin decreased to (16.7)% from 13.1% a year ago, including a non-cash goodwill impairment of $215.0 million in the fourth quarter of 2024 related to the Biologics Solutions reporting unit, which includes the Biologics Testing and CDMO businesses. Adjuste",
    "url": "https://finnhub.io/api/news?id=df4b151b1178c56312d74c8cd31ca6875d36d0110b74c4db92600ca2c91ab175",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740002288,
      "headline": "Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance",
      "id": 133194005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "On Wednesday, Charles River Laboratories International Inc (NYSE:CRL) reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million. In the fourth quarter of 2024, the operating margin decreased to (16.7)% from 13.1% a year ago, including a non-cash goodwill impairment of $215.0 million in the fourth quarter of 2024 related to the Biologics Solutions reporting unit, which includes the Biologics Testing and CDMO businesses. Adjuste",
      "url": "https://finnhub.io/api/news?id=df4b151b1178c56312d74c8cd31ca6875d36d0110b74c4db92600ca2c91ab175"
    }
  },
  {
    "ts": null,
    "headline": "CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall",
    "summary": "Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.",
    "url": "https://finnhub.io/api/news?id=23762f7eb36f2d65a3130bd0d78b1787e730d3800c8f1775abe1e4589e7c11f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739991060,
      "headline": "CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall",
      "id": 133191612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.",
      "url": "https://finnhub.io/api/news?id=23762f7eb36f2d65a3130bd0d78b1787e730d3800c8f1775abe1e4589e7c11f2"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories International Inc. stock outperforms competitors on strong trading day",
    "summary": "Charles River Laboratories International Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=879882453977ad05d10af12ac6e07b2c57c6e3e2bc0abf5ab3c93ac0c3cbedf2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739982600,
      "headline": "Charles River Laboratories International Inc. stock outperforms competitors on strong trading day",
      "id": 132821116,
      "image": "",
      "related": "CRL",
      "source": "MarketWatch",
      "summary": "Charles River Laboratories International Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=879882453977ad05d10af12ac6e07b2c57c6e3e2bc0abf5ab3c93ac0c3cbedf2"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories International, Inc. 2024 Q4 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Charles River Laboratories International, Inc.",
    "url": "https://finnhub.io/api/news?id=19941c31e4ab78334d006191c3f512dbd1cfa92a8c175b8f7dfbebeaa3599e25",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739977458,
      "headline": "Charles River Laboratories International, Inc. 2024 Q4 - Results - Earnings Call Presentation",
      "id": 132790768,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Charles River Laboratories International, Inc.",
      "url": "https://finnhub.io/api/news?id=19941c31e4ab78334d006191c3f512dbd1cfa92a8c175b8f7dfbebeaa3599e25"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript",
    "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call February 19, 2025 8:30 AM ETCompany ParticipantsTodd Spencer - Vice...",
    "url": "https://finnhub.io/api/news?id=68ba975b6ed64da0df17dbecef505b3292580077bed8af64ab3d72e038f31d05",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739977391,
      "headline": "Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript",
      "id": 132790769,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call February 19, 2025 8:30 AM ETCompany ParticipantsTodd Spencer - Vice...",
      "url": "https://finnhub.io/api/news?id=68ba975b6ed64da0df17dbecef505b3292580077bed8af64ab3d72e038f31d05"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics",
    "summary": "The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=54b6d13dd0d1f94c79e52e8167e029bf4dd9db1354f0f32034ab4dc56f1826db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739975423,
      "headline": "Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics",
      "id": 133194007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=54b6d13dd0d1f94c79e52e8167e029bf4dd9db1354f0f32034ab4dc56f1826db"
    }
  },
  {
    "ts": null,
    "headline": "Charles River beats quarterly estimates on stable demand for drug development services",
    "summary": "Contract research firms such as Charles River have noted reduced spending from biotech clients in the past two years.  Recent interest rate cuts are likely to improve funding environment for biotech companies, as borrowing costs might ease.  However, some life sciences firms have indicated that despite the rate cuts, smaller biotech clients will be cautious with their investments.",
    "url": "https://finnhub.io/api/news?id=cd78279cec6d81bc7a28c6a2343747e68dc51354d4d6b7511a0bec4e94f5df55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739970680,
      "headline": "Charles River beats quarterly estimates on stable demand for drug development services",
      "id": 133194008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Contract research firms such as Charles River have noted reduced spending from biotech clients in the past two years.  Recent interest rate cuts are likely to improve funding environment for biotech companies, as borrowing costs might ease.  However, some life sciences firms have indicated that despite the rate cuts, smaller biotech clients will be cautious with their investments.",
      "url": "https://finnhub.io/api/news?id=cd78279cec6d81bc7a28c6a2343747e68dc51354d4d6b7511a0bec4e94f5df55"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates",
    "summary": "Charles River (CRL) delivered earnings and revenue surprises of 6.40% and 2.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=f3603a29d59c810b306d9e108f51a49033afc3f38dbd964ac2f9e5d191a7f585",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739970606,
      "headline": "Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates",
      "id": 133194009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River (CRL) delivered earnings and revenue surprises of 6.40% and 2.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=f3603a29d59c810b306d9e108f51a49033afc3f38dbd964ac2f9e5d191a7f585"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4",
    "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.1% year on year to $1.00 billion. Its non-GAAP profit of $2.66 per share was 5.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=cf84a25fe1240b3dea77e80bd9211dac8eb2080279100e34fdb7b4e8ff64db27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739968078,
      "headline": "Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4",
      "id": 133194010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.1% year on year to $1.00 billion. Its non-GAAP profit of $2.66 per share was 5.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=cf84a25fe1240b3dea77e80bd9211dac8eb2080279100e34fdb7b4e8ff64db27"
    }
  },
  {
    "ts": null,
    "headline": "Charles River: Q4 Earnings Snapshot",
    "summary": "The Wilmington, Massachusetts-based company said it had a loss of $4.22 per share. Earnings, adjusted for non-recurring costs, were $2.66 per share. The results topped Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=6b421329fc869e0d94ff8a6ce17c2c36517fc858342a43d10f8c5f9c95340c06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739967723,
      "headline": "Charles River: Q4 Earnings Snapshot",
      "id": 133194011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "The Wilmington, Massachusetts-based company said it had a loss of $4.22 per share. Earnings, adjusted for non-recurring costs, were $2.66 per share. The results topped Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=6b421329fc869e0d94ff8a6ce17c2c36517fc858342a43d10f8c5f9c95340c06"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance",
    "summary": "WILMINGTON, Mass., February 19, 2025--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance",
    "url": "https://finnhub.io/api/news?id=5a9060ae055c38fd7030f1f654b79e1d381e155575979d65bbcbf6e30d791e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739966400,
      "headline": "Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance",
      "id": 133194012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "WILMINGTON, Mass., February 19, 2025--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance",
      "url": "https://finnhub.io/api/news?id=5a9060ae055c38fd7030f1f654b79e1d381e155575979d65bbcbf6e30d791e4a"
    }
  }
]